الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 136 |  |  |
| | | from | 136 | | |
Abstract
U
reteroscopy (URS) is one of the most common procedures performed for upper and lower ureteral disorders. However, URS is associated with possible risks and cmplications.
To facilitate ureteral stone extraction and decrease post-operative complications, recent studies have recommended a medical expelling therapy (MET) with antispasmodics (hyoscine-N-butylbromide), calcium antagonists (nifedipine), and α-1 blockers (tamsulosin).
Based on these observations, we hypothesized that administration of these drugs before endoscopic treatment of ureteral stones may increase the success rate of the procedure and decrease operative and postoperative complications.
In our analysis, the aim of our study is to assess the effectiveness of antispasmodics (hyoscine-N-butylbromide), α-blockers (tamsulosin), placebo as control, as preoperative medications for ureteral dilatation before semirigid ureteroscopic stone surgery.
This prospective randomized control clinical study conducted on 90 patients admitted from Urology department, Faculty of Medicine, Ain Shams University hospitals in a period of 6 months starting from March 2022 till September 2022; they were randomized into 3 groups 30 patients per group: group (A) received Tamsulosin 0.4 mg once daily for 7 days, group (B) received Hyoscine-N-butylbromide 10 mg three times per day for 7 days, Gathering (C) received Placebo.
The study showed that administration of preoperative Tamsulosin or Hyoscine-N-butylbromide significantly decreases the need of ureteric orifice dilatation, increases the rate of successful ureteral access to stone.
Furthermore, the operation time and the need of double J stent insertion significantly decrease with Tasmulosin or Hyoscine-N-butylbromide versus Placebo.
Operative and postoperative complications significantly decrease while using Tamsulosin or Hyoscine-N-butylbromide versus Placebo.